Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has issued an announcement.
Ascentage Pharma Group International, a global commercial-stage biopharmaceutical company listed on NASDAQ and HKEX, focuses on oncology therapies targeting apoptotic pathways and kinases, with lead drugs Olverembatinib for various forms of CML and Lisaftoclax for CLL/SLL already approved and reimbursed or commercialized in China. The company is advancing multiple global Phase III registrational trials across leukemia, lymphoma, GIST and MDS, while on February 9, 2026 it announced that its management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11–12, signaling efforts to deepen engagement with global investors and highlight its expanding late-stage oncology portfolio.
The most recent analyst rating on (AAPG) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.
Spark’s Take on AAPG Stock
According to Spark, TipRanks’ AI Analyst, AAPG is a Neutral.
The score is primarily held back by weak financial quality (ongoing losses, negative cash flow, and high leverage risk) and bearish technical conditions (negative MACD and price below key moving averages). Rapid revenue growth provides some offset, but valuation signals are limited due to negative earnings and no dividend data.
To see Spark’s full report on AAPG stock, click here.
More about Ascentage Pharma Group International Unsponsored ADR
Ascentage Pharma Group International is a global, commercial-stage integrated biopharmaceutical company focused on discovering, developing and commercializing novel, differentiated therapies for cancers with significant unmet medical needs. Its pipeline includes apoptosis-targeting agents such as Bcl-2 and MDM2-p53 inhibitors and next-generation kinase inhibitors, led by Olverembatinib for CML and Lisaftoclax for hematologic malignancies, both already approved and commercialized in China.
Average Trading Volume: 4,185
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.22B
See more data about AAPG stock on TipRanks’ Stock Analysis page.